More that 233 of 331 or > 30% with an NWBO estimate of several months before the 233 is reached. My concern is that since this appears to be effectively a cure for mesymal subgroup (almost 50% of the GBM patients) it could end up taking far longer than several months. Lets hope the FDA (especially with Trump focus on early access to new treatment for diseases without any other effective treatments) steps in and approves so we are not left waiting perhaps years to reach 233 . . . that would be utterly ludicrous for the FDA to not do that.
News 
Market Data 
Discover 
